Follow us on Social Media for updates about all things Gentronix
A WEALTH OF EXPERIENCE
As Chairman of the Board, Alan provides leadership to the Board of Directors and strategic input into the growth and delivery of the business. Alan has a wealth of experience in scaling service businesses, gained over 20 years from senior executive roles within major CROs. Alan also has extensive experience of raising growth capital and delivering buy and build strategies with support of private equity.
MATT TATEManaging Director
Matt has been with the business since 2006. Initially working on the development of our screening assays and earning a PhD in genetic toxicology, Matt transitioned to the commercial side of the business, working globally with clients to implement the most appropriate testing strategies for their needs. He now leads the business, developing our overall strategy and delivering our plan to build an expert predictive toxicology CRO, whilst remaining passionate about toxicology and engaging with our clients to meet their challenges.
NICK BILLINTONOperations Director
Nick is one of the company’s originating scientists, initially as a PhD student in the founding lab. Post-PhD, Nick led the research efforts to develop the GreenScreen® HC & BlueScreen™ HC technologies, and then the transition of the business to a CRO. Providing project management and scientific leadership, Nick implemented GLP compliance in the organisation. As Operations Director, Nick continues to ensure our commitment to expert delivery of high quality science is maintained.
PAUL RAWLINSONLead Toxicologist
Paul joined Gentronix in 2018 after working as an R&D and Regulatory Toxicologist at a major agrochemical R&D company for 11 years. Prior to that he had experience in the cosmetics industry and in pharmaceutical literature services. Paul’s skills and experience includes designing testing strategies, data interpretation, product development and regulatory product safety advocacy. The accumulation of all of Paul’s work and experience allows him to support clients from early-stage drug discovery through to product life cycle management.
LAURA HINTONOperations Director
Laura recently joined Gentronix as an Operations Director to work towards delivering ambitious growth plans as part of the senior leadership team. During the early stages of her career Laura worked as a DMPK scientist in a leading pharmaceutical company and gained a PhD in pharmacokinetics. It was the transition into a role in a specialist CRO that led to Laura developing an interest in the operational aspects of the CRO business and latterly becoming their Director of Scientific Operations. With 13 years of contract research experience, Laura’s interests now lie in the development and scaling of effective organisations to enable sustainable growth and timely delivery of high quality services.
JOHN YATESFinancial Director
John is a highly experienced Financial Director, with an extensive track record in supporting the financial management of SME sector organisations. John qualified as a Chartered Accountant at KPMG, and then spent several years in industry before establishing his own consultancy practice via which he worked at Board level for various technology-based businesses both in the UK, Europe and the USA. During this time, he has acted in a series of funding transactions and has also participated in a number of company disposals. He joined the Board of Gentronix Limited 2001, and has been Finance Director from 2004. He also acts as the Company Secretary.
ELIAS HALKES-WELLSTEADBusiness Development Manager
Elias joined Gentronix in 2020 as a Business Development Manager, having previously worked in sales development within a genomic stabilisation devices company in Canada. Following the completion of his Masters in Genetic Toxicology and experience in the micronucleus assay and benchmark dose response analysis, Elias is well positioned to assist clients in assay selection in both a GLP and Non-GLP framework.